Proteome Profiler Human Phospho-RTK Array Kit

Contains 4 membranes - each spotted in duplicate with 49 different RTK antibodies
  (149 citations)
(1 Review)
    
Datasheet / CoA / SDS
Product Details
Citations (149)
FAQs
Supplemental Products
Reviews
Kit Summary

A membrane-based antibody array for the parallel determination of the relative phosphorylation of human receptor tyrosine kinases. Validated for analyte detection in cell lysates.

Troubleshooting Guide

Key Benefits

  • Detects phosphorylation of 49 human receptor tyrosine kinases simultaneously
  • Requires no specialized equipment
 

 

Principle of the Assay

The Proteome Profiler Human Phospho-RTK Array Kit is a membrane-based sandwich immunoassay. Capture antibodies spotted in duplicate on nitrocellulose membranes bind to specific target proteins present in the sample (Step 1). Tyrosine phosphorylation of the captured proteins is detected with an HRP-conjugated pan phospho-tyrosine antibody (Step 2) and then visualized using chemiluminescent detection reagents (Step 3). The signal produced is proportional to the amount phosphorylation in the bound analyte.

Why Use an Antibody Array to Detect Receptor Phosphorylation?

Determining the phosphorylation of multiple receptors in a single sample can be expensive, time consuming and can require specialized equipment. Performing multiple immunoprecipitations and Western blots requires time, labor, and reagents. The use of a multiplex antibody array to detect multiple phosphorylations in a single sample can be cost-effective and also save time and sample.

 
Kit Contents
  • 4 Array Membranes
  • 4-Well Multi-dish
  • Array Buffers
  • Lysis Buffer
  • Wash Buffer
  • Anti-Phospho-Tyrosine-HRP Detection Antibody
  • Chemiluminescent Detection Reagents
  • Transparency Overlay Template
  • Detailed Protocol

For a complete list of the kit contents and necessary materials, please see the Materials Provided/Other Supplies Required sections of the product datasheet.

Stability and Storage

Store the unopened kit at 2 °C to 8 °C. Do not use past kit expiration date.

 
Simultaneously detect the relative phosphorylation of these RTKs in a single sample
ALK/CD246 EphB4 MuSK
Axl EphB6 PDGF R alpha
DDR1 ErbB2 PDGF R beta
DDR2 ErbB3 c-Ret
Dtk ErbB4 ROR1
EGF R FGF R1 ROR2
EphA1 FGF R2 alpha Ryk
EphA2 FGF R3 SCF R/c-kit
EphA3 FGF R4 Tie-1
EphA4 Flt-3/Flk-2 Tie-2
EphA5 HGF R/c-MET TrkA
EphA6 IGF-I R TrkB
EphA7 Insulin R/CD220 TrkC
EphA10 M-CSF R VEGF R1/Flt-1
EphB1 Mer VEGF R2/KDR
EphB2 MSP R/Ron VEGF R3/Flt-4
EphB3    
 

Assays for Analytes represented in the Proteome Profiler Human Phospho-RTK Array Kit

 
Analyte Quantikine® ELISA Kits DuoSet® ELISA Development System DuoSet® IC ELISA Development Systems (Total) DuoSet® IC ELISA Development Systems (Phospho) Cell-based ELISA Kits
ALK/CD246          
Axl   DY154 DYC1643    
DDR1     DYC2396 DYC5859  
DDR2     DYC2538 DYC6170  
Dtk   DY859      
EGF R DEGFR0 DY231 DYC1854 DYC1095B  
EphA1     DYC638    
EphA2     DYC3035 DYC4056  
EphA3          
EphA4     DYC3038 DYC4057  
EphA5          
EphA6          
EphA7          
EphA10          
EphB1          
EphB2          
EphB3          
EphB4     DYC3038 DYC4057  
ErbB2   DY1129 DYC1129 DYC1768  
ErbB3   DY348 DYC234 DYC1769 KCB5677
ErbB4     DYC1133 DYC2115
ErbB6          
FGF R1       DYC5079  
FGF R2 alpha     DYC665 DYC684  
FGF R3     DYC766 DYC2719  
FGF R4     DYC685 DYC5516  
Flt-3/Flk     DYC912 DYC368  
HGF R/c-MET   DY358 DYC358 DYC2480  
IGF-I R   DY391 DYC305 DYC1770  
Insulin R/CD220     DYC1544 DYC2718  
M-CSF R   DY329 DYC329 DYC3268  
Mer   DY6488 DYC891 DYC2579  
MSP R/Ron     DYC691 DYC1947  
MuSK          
PDGF R alpha     DYC322 DYC2114  
Ret          
ROR1          
ROR2          
Ryk          
PDGF R beta     DYC385 DYC1767  
DYC3096  
SCF R/c-kit DSCR00 DY332 DYC332 DYC3527  
Tie-1   DY5907      
Tie-2 DTE200 DY5159   DCY2720  
TrkA     DYC175 DYC2578  
TrkB     DYC397 DYC688  
TrkC     DYC373    
VEGF R1/Flt-1 DVR100B DY321B   DYC4170  
VEGF R2/KDR DVR200 DY357 DYC1780 DYC1766  
VEGF R3/Flt-4   DY349 DYC3491 DYC2724  
 
Data Examples
Figure 1. KATO-III human gastric carcinoma cells were either untreated or treated with 100 ng/mL rhFGF acidic and 1 μg/mL heparin for 15 minutes.
View Larger Image

Figure 1. KATO-III human gastric carcinoma cells were either untreated or treated with 100 ng/mL rhFGF acidic and 1 μg/mL heparin for 15 minutes. Cells for rhFGF acidic/Heparin treatment either received pre-treatment with the reversible FGF R and VEGF R inhibitor PD 173074 (Tocris, Catalog # 3044), or with the FGF R-specific tyrosine kinase inhibitor SU 5402 (Tocris, Catalog # 3300), or no pre-treatment.

Figure 2. The Human Phospho-RTK Array is specific for ErbB2, ErbB3, and ErbB4 as shown by receptor competition.
View Larger Image

Figure 2. The Human Phospho-RTK Array is specific for ErbB2, ErbB3, and ErbB4 as shown by receptor competition. MDA-MB-453 human breast cancer cells were treated with 100 ng/mL of rhNRG1-beta1/HRG1-beta1 (R&D Systems, Catalog # 396-HB) for 5 minutes. 5 µg of rhErbB2 (R&D Systems, Catalog # 1129-ER), rhErbB3 (R&D Systems, Catalog # 348-RB), or rhErbB4 (R&D Systems, Catalog # 1131-ER) extracellular domains were added to 50 µg of lysate and analyzed using the Human Phospho-RTK Array. Competition of a particular ErbB receptor was observed only with the corresponding recombinant soluble receptor.


Product Datasheets

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

Preparation and Storage
  • Stability & Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: RTK Assay Kits
Receptor Tyrosine Kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors, neurotrophic factors, and other extracellular signaling molecules. Upon ligand binding, they undergo tyrosine phosphorylation at specific residues in the cytoplasmic tail. This leads to the binding of protein substrates and/or the establishment docking sites for adaptor proteins involved in RTK-mediated signal transduction. RTKs have critical functions in several developmental processes including regulating cell survival, proliferation, and motility. When unregulated, they play prominent roles in cancer formation. R&D Systems offers several different multiplex assay formats that allow the user to assess the activity of many RTKs in a single sample. Available RTK multiplex kits include bead-based multiplex kits for the Luminex platform, membrane-based antibody arrays, and microplate-based antibody arrays.
  • Alternate Names:
    RTK Assay Kits
Related Research Areas
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

149 Citations: Showing 1 - 10
Filter your results:

Species
Sample Type
  1. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals
    Authors: SN Jung, HS Lim, L Liu, JW Chang, YC Lim, KS Rha, BS Koo
    Sci Rep, 2018;8(1):2718.  2018
  2. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
    Authors: H Kotani, Y Adachi, H Kitai, S Tomida, H Bando, AC Faber, T Yoshino, DC Voon, S Yano, H Ebi
    Oncogene, 2018;0(0):.  2018
  3. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
    Authors: R Herr, S Halbach, M Heizmann, H Busch, M Boerries, T Brummer
    Oncogene, 2018;0(0):.  2018
  4. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
    Authors: K Ninomiya, K Ohashi, G Makimoto, S Tomida, H Higo, H Kayatani, T Ninomiya, T Kubo, E Ichihara, K Hotta, M Tabata, Y Maeda, K Kiura
    Sci Rep, 2018;8(1):1955.  2018
  5. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma
    Authors: F Mao, C Holmlund, M Faraz, W Wang, T Bergenheim, S Kvarnbrink, M Johansson, R Henriksson, H Hedman
    Oncogenesis, 2018;7(2):13.  2018
  6. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism
    Authors: A Lampada, J O'Prey, G Szabadkai, KM Ryan, D Hochhauser, P Salomoni
    Cell Death Differ., 2017;0(0):.  2017
  7. MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer
    Authors: S Nanjo, S Arai, W Wang, S Takeuchi, T Yamada, A Hata, N Katakami, Y Okada, S Yano
    Mol. Cancer Ther, 2017;0(0):.  2017
  8. Insulin-like Growth Factor-1 signalling is essential for Mitochondrial Biogenesis and Mitophagy in cancer cells
    Authors: A Lyons, M Coleman, S Riis, C Favre, CH O'Flanagan, AV Zhdanov, DB Papkovsky, SD Hursting, R O'Connor
    J. Biol. Chem., 2017;0(0):.  2017
  9. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
    Authors: L Klameth, B Rath, G Hamilton
    J Cancer, 2017;8(10):1733-1743.  2017
  10. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer
    Authors: C Li, B Singh, R Graves-Dea, H Ma, A Starchenko, WH Fry, Y Lu, Y Wang, G Bogatcheva, MP Khan, GL Milne, S Zhao, GD Ayers, N Li, H Hu, MK Washington, TJ Yeatman, OG McDonald, Q Liu, RJ Coffey
    Proc. Natl. Acad. Sci. U.S.A, 2017;0(0):.  2017
  11. Amplification of EGFR wild type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
    Authors: S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto, K Masuzawa, I Kawada, K Naoki, S Matsumoto, S Mimaki, S Ikemura, K Goto, T Betsuyaku, K Soejima
    Cancer Res, 2017;0(0):.  2017
  12. Altered Met Receptor Phosphorylation and LRP1 Mediated Uptake in Cells Lacking Carbohydrate-Dependent Lysosomal Targeting
    Authors: M Aarnio-Pet, P Zhao, SH Yu, C Christian, H Flanagan-S, L Wells, R Steet
    J. Biol. Chem., 2017;0(0):.  2017
  13. BCL6 promotes glioma and serves as a therapeutic target
    Authors: L Xu, Y Chen, M Dutra-Clar, A Mayakonda, M Hazawa, SE Savinoff, N Doan, JW Said, WH Yong, A Watkins, H Yang, LW Ding, YY Jiang, JW Tyner, J Ching, JP Kovalik, V Madan, SL Chan, M Müschen, JJ Breunig, DC Lin, HP Koeffler
    Proc. Natl. Acad. Sci. U.S.A, 2017;0(0):.  2017
  14. Ectodomain Shedding of the Cell Adhesion Molecule Nectin-4 in Ovarian Cancer is Mediated by ADAM10 and ADAM17
    Authors: PC Buchanan, KL Boylan, B Walcheck, R Heinze, MA Geller, PA Argenta, AP Skubitz
    J. Biol. Chem, 2017;0(0):.  2017
  15. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
    Authors: SS Yadav, J Li, JA Stockert, B Herzog, J O'Connor, L Garzon-Man, R Parsons, AK Tewari, KK Yadav
    Transl Oncol, 2017;10(3):357-366.  2017
  16. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS
    Authors: E Saintas, L Abrahams, GT Ahmad, AM Ajakaiye, AS AlHumaidi, C Ashmore-Ha, I Clark, UK Dura, CN Fixmer, C Ike-Morris, M Mato Prado, D Mccullough, S Mishra, KM Schöler, H Timur, MD Williamson, M Alatsatian, B Bahsoun, E Blackburn, CE Hogwood, PE Lithgow, M Rowe, L Yiangou, F Rothweiler, J Cinatl, R Zehner, AJ Baines, MD Garrett, CW Gourlay, DK Griffin, WJ Gullick, E Hargreaves, MJ Howard, DR Lloyd, JS Rossman, CM Smales, AD Tsaousis, T von der Ha, MN Wass, M Michaelis
    PLoS ONE, 2017;12(2):e0172140.  2017
  17. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation
    Authors: K Miyata, A Takemoto, S Okumura, M Nishio, N Fujita
    Sci Rep, 2017;7(1):4059.  2017
  18. Dual�Targeting�of�Insulin�Receptor�and�KIT�in�Imatinib-Resistant�Gastrointestinal�Stromal�Tumors
    Authors: W Chen, Y Kuang, HB Qiu, Z Cao, Y Tu, Q Sheng, G Eilers, Q He, HL Li, M Zhu, Y Wang, R Zhang, Y Wu, F Meng, JA Fletcher, WB Ou
    Cancer Res., 2017;0(0):.  2017
  19. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling
    Authors: HP Hsu, MD Lai, JC Lee, MC Yen, TY Weng, WC Chen, JH Fang, YL Chen
    Sci Rep, 2017;7(1):5823.  2017
  20. Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells
    Authors: R Mansouri, Y Jouan, E Hay, C Blin-Wakka, M Frain, A Ostertag, C Le Henaff, C Marty, V Geoffroy, PJ Marie, M Cohen-Sola, D Modrowski
    Cell Death Dis, 2017;8(6):e2902.  2017
  21. Piperlongumine downregulates the expression of HER family in breast cancer cells
    Authors: HO Jin, JA Park, HA Kim, YH Chang, YJ Hong, IC Park, JK Lee
    Biochem. Biophys. Res. Commun., 2017;0(0):.  2017
  22. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest
    Authors: K Oura, T Tadokoro, S Fujihara, A Morishita, T Chiyo, E Samukawa, Y Yamana, K Fujita, T Sakamoto, T Nomura, H Yoneyama, H Kobara, H Mori, H Iwama, K Okano, Y Suzuki, T Masaki
    Oncol. Rep., 2017;38(5):2825-2835.  2017
  23. Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol
    Authors: HE Pearson, M Iida, RA Orbuch, NK McDaniel, KP Nickel, RJ Kimple, J Arbiser, DL Wheeler
    Mol. Cancer Ther., 2017;0(0):.  2017
  24. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors
    Authors: C Chauvin, A Leruste, A Tauziede-E, M Andrianter, D Surdez, A Lescure, ZY Han, E Anthony, W Richer, S Baulande, M Bohec, S Zaidi, MM Aynaud, L Maillot, J Masliah-Pl, S Cairo, S Roman-Roma, O Delattre, E Del Nery, F Bourdeaut
    Cell Rep, 2017;21(7):1737-1745.  2017
  25. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming
    Authors: R Adelaiye-O, J Budka, NP Damayanti, J Arrington, MW Ferris, CC Hsu, S Chintala, AR Orillion, KM Miles, L Shen, M Elbanna, E Ciamporcer, S Arisa, P Pettazzoni, GF Draetta, M Seshadri, BA Hancock, M Radovich, J Kota, M Buck, H Keilhack, BP McCarthy, SA Persohn, PR Territo, Y Zang, J Irudayaraj, AW Tao, P Hollenhors, R Pili
    Cancer Res., 2017;0(0):.  2017
  26. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis
    Authors: K Noh, LS Mangala, HD Han, N Zhang, S Pradeep, SY Wu, S Ma, E Mora, R Rupaimoole, D Jiang, Y Wen, MMK Shahzad, Y Lyons, M Cho, W Hu, AS Nagaraja, M Haemmerle, CSL Mak, X Chen, KM Gharpure, H Deng, W Xiong, CV Kingsley, J Liu, N Jennings, MJ Birrer, RR Bouchard, G Lopez-Bere, RL Coleman, Z An, AK Sood
    Cell Rep, 2017;21(10):2785-2795.  2017
  27. Protein C receptor stimulates multiple signaling pathways in breast cancer cells
    Authors: D Wang, C Liu, J Wang, Y Jia, X Hu, H Jiang, ZM Shao, YA Zeng
    J. Biol. Chem., 2017;0(0):.  2017
  28. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases
    Authors: G Cassinelli, E Favini, L Dal Bo, M Tortoreto, M De Maglie, G Dagrada, S Pilotti, F Zunino, N Zaffaroni, C Lanzi
    Oncotarget, 2016;7(30):47848-47863.  2016
  29. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15
    PLoS ONE, 2016;11(5):e0155561.  2016
  30. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor
    Nat Commun, 2016;7(0):12038.  2016
  31. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma
    Authors: M Huang, T Liu, P Ma, RA Mitteer, Z Zhang, HJ Kim, E Yeo, D Zhang, P Cai, C Li, L Zhang, B Zhao, L Roccogrand, DM O'Rourke, N Dahmane, Y Gong, C Koumenis, Y Fan
    J Clin Invest, 2016;0(0):.  2016
  32. Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway.
    Authors: Szymanska E, Skowronek A, Miaczynska M
    Cell Signal, 2016;28(1):160-71.  2016
  33. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Authors: Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, Munoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill R, Roche J, Drabkin H, Haura E
    PLoS ONE, 2016;11(1):e0147344.  2016
  34. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the Downregulation of Epidermal Growth Factor Receptor
    Authors: Maurizio Bifulco
    Int. J. Cancer, 2016;0(0):.  2016
  35. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases
    Authors: Y Xu, K Wang, Q Yu
    Oncotarget, 2016;7(43):70080-70091.  2016
  36. EphA2 is a functional receptor for the growth factor progranulin
    Authors: Thomas Neill
    J. Cell Biol, 2016;215(5):687-703.  2016
  37. Activation of EGFR Bypass Signaling by TGF? Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
    Authors: T Tani, H Yasuda, J Hamamoto, A Kuroda, D Arai, K Ishioka, K Ohgino, M Miyawaki, I Kawada, K Naoki, Y Hayashi, T Betsuyaku, K Soejima
    Mol. Cancer Ther., 2016;15(1):162-71.  2016
  38. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1
    Authors: T Yamaguchi, C Lu, L Ida, K Yanagisawa, J Usukura, J Cheng, N Hotta, Y Shimada, H Isomura, M Suzuki, T Fujimoto, T Takahashi
    Nat Commun, 2016;7(0):10060.  2016
  39. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Authors: Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw C, Miao B, Frederick D, Wargo J, Flaherty K, Jonsson G, Tsao H
    J Invest Dermatol, 2015;135(7):1863-72.  2015
  40. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Authors: Cohen N, Zeng S, Seifert A, Kim T, Sorenson E, Greer J, Beckman M, Santamaria-Barria J, Crawley M, Green B, Rossi F, Besmer P, Antonescu C, DeMatteo R
    Cancer Res, 2015;75(10):2061-70.  2015
  41. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Authors: Song A, Kim T, Kim D, Kim S, Keam B, Lee S, Heo D
    Clin Cancer Res, 2015;21(10):2379-87.  2015
  42. Biologically active LIL proteins built with minimal chemical diversity.
    Authors: Heim E, Marston J, Federman R, Edwards A, Karabadzhak A, Petti L, Engelman D, DiMaio D
    Proc Natl Acad Sci U S A, 2015;112(34):E4717-25.  2015
  43. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
    Authors: Puzanov I, Lindsay C, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans T
    Clin Cancer Res, 2015;21(4):701-11.  2015
  44. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Authors: Broecker-Preuss M, Muller S, Britten M, Worm K, Kurt Werner S, Mann K, Fuhrer D
    BMC Cancer, 2015;15(0):184.  2015
  45. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation.
    Authors: Tworkoski K, Raab-Traub N
    J Virol, 2015;89(5):2590-602.  2015
  46. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
    Authors: Wang, J, Mikse, O, Liao, R G, Li, Y, Tan, L, Janne, P A, Gray, N S, Wong, K-K, Hammerman, P S
    Oncogene, 2015;34(17):2167-77.  2015
  47. Artificial human Met agonists based on macrocycle scaffolds.
    Authors: Ito, Kenichir, Sakai, Katsuya, Suzuki, Yoshinor, Ozawa, Naoya, Hatta, Tomohisa, Natsume, Tohru, Matsumoto, Kunio, Suga, Hiroaki
    Nat Commun, 2015;6(0):6373.  2015
  48. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
    Authors: Wu, Jia-Ru, Hu, Chi-Tan, You, Ren-In, Ma, Pei-Ling, Pan, Siou-Mei, Lee, Ming-Che, Wu, Wen-Shen
    PLoS ONE, 2015;10(1):e0114495.  2015
  49. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array.
    Authors: Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama J
    PLoS ONE, 2015;10(8):e0134948.  2015
  50. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.
    Authors: Zemskova M, Song J, Cen B, Cerda-Infante J, Montecinos V, Kraft A
    Cell Signal, 2015;27(1):135-46.  2015
  51. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI.
    Authors: Laukkanen, Mikko O, Cammarota, Francesc, Esposito, Tiziana, Salvatore, Marco, Castellone, Maria D
    PLoS ONE, 2015;10(3):e0121441.  2015
  52. Improvement of human keratinocyte migration by a redox active bioelectric dressing.
    Authors: Banerjee J, Das Ghatak P, Roy S, Khanna S, Sequin E, Bellman K, Dickinson B, Suri P, Subramaniam V, Chang C, Sen C
    PLoS ONE, 2014;9(3):e89239.  2014
  53. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
    Authors: Calero R, Morchon E, Johnsen J, Serrano R
    PLoS ONE, 2014;9(4):e95628.  2014
  54. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Authors: Montero J, Esparis-Ogando A, Re-Louhau M, Seoane S, Abad M, Calero R, Ocana A, Pandiella A
    Oncogene, 2014;33(2):148-56.  2014
  55. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Authors: Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, Schiller M, Hauschild A, Hein R, Kampgen E, Kellner I, Leverkus M, Becker J, Strobel P, Schadendorf D
    Clin Cancer Res, 2014;20(2):499-510.  2014
  56. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
    Authors: Cuenca-Lopez M, Montero J, Morales J, Prat A, Pandiella A, Ocana A
    BMC Cancer, 2014;14(0):302.  2014
  57. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
    Authors: Wang, Lu-Kai, Hsiao, Tzu-Hung, Hong, Tse-Ming, Chen, Hsuan-Yu, Kao, Shih-Han, Wang, Wen-Lung, Yu, Sung-Lia, Lin, Ching-We, Yang, Pan-Chyr
    PLoS ONE, 2014;9(5):e96765.  2014
  58. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency.
    Authors: Son M, Seol B, Han Y, Cho Y
    Hum Mol Genet, 2014;23(7):1802-16.  2014
  59. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Authors: Li L, Chakraborty S, Yang C, Hatanpaa K, Cipher D, Puliyappadamba V, Rehman A, Jiwani A, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle S, Kesari S, Boothman D, Habib A
    Oncogene, 2014;33(33):4253-64.  2014
  60. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRbeta aptamer.
    Authors: Camorani S, Esposito C, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L
    Mol Ther, 2014;22(4):828-41.  2014
  61. Expressed glycosylphosphatidylinositol-anchored horseradish peroxidase identifies co-clustering molecules in individual lipid raft domains.
    Authors: Miyagawa-Yamaguchi, Arisa, Kotani, Norihiro, Honke, Koichi
    PLoS ONE, 2014;9(3):e93054.  2014
  62. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells.
    Authors: Okon I, Coughlan K, Zou M
    J Biol Chem, 2014;289(3):1639-48.  2014
  63. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells.
    Authors: Sakanyan V, Angelini M, Le Bechec M, Lecocq M, Benaiteau F, Rousseau B, Gyulkhandanyan A, Gyulkhandanyan L, Loge C, Reiter E, Roussakis C, Fleury F
    Sci Rep, 2014;4(0):3977.  2014
  64. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
    Authors: Outani, Hidetats, Tanaka, Takaaki, Wakamatsu, Toru, Imura, Yoshinor, Hamada, Kenichir, Araki, Nobuhito, Itoh, Kazuyuki, Yoshikawa, Hideki, Naka, Norifumi
    BMC Cancer, 2014;14(0):455.  2014
  65. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy.
    Authors: Skoda J, Neradil J, Zitterbart K, Sterba J, Veselska R
    Oncol Rep, 2014;31(1):480-7.  2014
  66. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Authors: Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Fung C, Snoyman S, Hersey P, Long G, Kefford R, Rizos H
    Mol Oncol, 2014;8(3):544-54.  2014
  67. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor alpha.
    Authors: Lei H, Kazlauskas A
    Mol Cell Biol, 2014;34(1):110-22.  2014
  68. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality.
    Authors: Shiono, Masatosh, Kobayashi, Toshiyuk, Takahashi, Riichi, Ueda, Masatsug, Ishioka, Chikashi, Hino, Okio
    Sci Rep, 2014;4(0):5927.  2014
  69. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Authors: Imura, Yoshinor, Yasui, Hirohiko, Outani, Hidetats, Wakamatsu, Toru, Hamada, Kenichir, Nakai, Takaaki, Yamada, Shutaro, Myoui, Akira, Araki, Nobuhito, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, Naka, Norifumi
    Mol Cancer, 2014;13(0):185.  2014
  70. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
    Authors: Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty P, Wilson M, Hayden J, Keeney F, Nathanson K, Herlyn M
    Oncogene, 2014;33(14):1850-61.  2014
  71. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein.
    Authors: Krzyzaniak M, Zumstein M, Gerez J, Picotti P, Helenius A
    PLoS Pathog, 2013;9(4):e1003309.  2013
  72. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.
    Authors: Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy C, Wetzel K, George E, Popa M, Lilley S, Choudhury H, Gosling M, Wang L, Fitzgerald S, Borawski J, Baffoe J, Labow M, Gaither L, Bentires-Alj M
    Proc Natl Acad Sci U S A, 2013;110(11):E1026-34.  2013
  73. Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling.
    Authors: Kwon, Heung Su, Johnson, Thomas V, Joe, Myung Ku, Abu-Asab, Mones, Zhang, Jun, Chan, Chi Chao, Tomarev, Stanisla
    J Biol Chem, 2013;288(37):26357-71.  2013
  74. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration.
    Authors: Lee H, Bennett A
    Mol Cell Biol, 2013;33(7):1430-41.  2013
  75. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
    Authors: Drake J, Graham N, Lee J, Stoyanova T, Faltermeier C, Sud S, Titz B, Huang J, Pienta K, Graeber T, Witte O
    Proc Natl Acad Sci U S A, 2013;110(49):E4762-9.  2013
  76. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin.
    Authors: de-Freitas-Junior J, Carvalho S, Dias A, Oliveira P, Cabral J, Seruca R, Oliveira C, Morgado-Diaz J, Reis C, Pinho S
    PLoS ONE, 2013;8(11):e81579.  2013
  77. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Authors: Davies, Kurtis D, Mahale, Sakshi, Astling, David P, Aisner, Dara L, Le, Anh T, Hinz, Trista K, Vaishnavi, Aria, Bunn, Paul A J, Heasley, Lynn E, Tan, Aik-Choo, Camidge, D Ross, Varella-Garcia, Marileil, Doebele, Robert C
    PLoS ONE, 2013;8(12):e82236.  2013
  78. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.
    Authors: Lekawanvijit S, Kumfu S, Wang B, Manabe M, Nishijima F, Kelly D, Krum H, Kompa A
    PLoS ONE, 2013;8(12):e83687.  2013
  79. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.
    Authors: Lin, Shih-Pei, Lee, Yi-Ting, Wang, Jir-You, Miller, Stephani, Chiou, Shih-Hwa, Hung, Mien-Chi, Hung, Shih-Chi
    PLoS ONE, 2012;7(11):e49605.  2012
  80. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Authors: Oliveras-Ferraros C, Cufi S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA
    Br. J. Cancer, 2012;106(8):1406-14.  2012
  81. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.
    Authors: Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A, Mongiat M
    Oncogene, 2012;31(26):3136-47.  2012
  82. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
    Authors: Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura E
    Cancer Res, 2012;72(10):2501-11.  2012
  83. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.
    Authors: Ho A, Vasudeva S, Lae M, Saito T, Barbashina V, Antonescu C, Ladanyi M, Schwartz G
    Cancer Res, 2012;72(17):4515-25.  2012
  84. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Authors: Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H
    J. Invest. Dermatol., 2012;132(7):1850-9.  2012
  85. Fibroblast Growth Factor Receptor 3 (FGFR3) Associated with the CD20 Antigen Regulates the Rituximab-induced Proliferation Inhibition in B-cell Lymphoma Cells.
    Authors: Kotani N, Ishiura Y, Yamashita R, Ohnishi T, Honke K
    J Biol Chem, 2012;287(44):37109-18.  2012
  86. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
    Clin. Cancer Res., 2012;18(17):4570-9.  2012
  87. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
    Authors: Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL
    Proc. Natl. Acad. Sci. U.S.A., 2012;109(8):2718-23.  2012
  88. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.
    Authors: Purushothaman, Anurag, Babitz, Stephen, Sanderson, Ralph D
    J Biol Chem, 2012;287(49):41288-96.  2012
  89. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway.
    J. Immunol., 2012;189(5):2563-73.  2012
  90. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
    Authors: Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J, Johnson N, Granger D, Jordan N, Darr D, Usary J, Kuan P, Smalley D, Major B, He X, Hoadley K, Zhou B, Sharpless N, Perou C, Kim W, Gomez S, Chen X, Jin J, Frye S, Earp H, Graves L, Johnson G
    Cell, 2012;149(2):307-21.  2012
  91. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency.
    Authors: Ball SG, Shuttleworth A, Kielty CM
    Stem Cells, 2012;30(3):548-60.  2012
  92. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Authors: Joshi, Avadhut, Loilome, Watchari, Siu, I-Mei, Tyler, Betty, Gallia, Gary L, Riggins, Gregory
    PLoS ONE, 2012;7(10):e44372.  2012
  93. Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells.
    Authors: Ding VM, Boersema PJ, Foong LY
    PLoS ONE, 2011;6(3):e17538.  2011
  94. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2.
    Authors: Tanabe H, Kuribayashi K, Tsuji N
    Int. J. Oncol., 2011;39(1):33-40.  2011
  95. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
    Authors: Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF
    Nat. Med., 2011;17(5):589-95.  2011
  96. 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer.
    Authors: McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC
    Clin. Cancer Res., 2011;17(10):3332-40.  2011
  97. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.
    Authors: Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ
    Oncogene, 2011;30(13):1542-50.  2011
  98. The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation.
    Authors: Karki R, Lang SM, Means RE
    PLoS Pathog., 2011;7(4):e1001331.  2011
  99. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
    Authors: Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gomez-Martinez A, Garcia-Morales P, Ferragut JA, Martinez-Lacaci I
    Exp. Cell Res., 2011;317(10):1476-89.  2011
  100. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Authors: Poulikakos PI, Persaud Y, Janakiraman M
    Nature, 2011;480(7377):387-90.  2011
  101. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
    Authors: Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA
    Neoplasia, 2011;13(1):12-22.  2011
  102. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.
    Authors: Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Oberg Ã…, Van Guelpen B, Rutegard J, Stenling R, Palmqvist R
    Am. J. Pathol., 2011;178(3):1387-94.  2011
  103. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
    Authors: Tanizaki J, Okamoto I, Sakai K
    Br. J. Cancer, 2011;105(6):807-13.  2011
  104. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
    Authors: Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J
    J. Clin. Invest., 2011;121(11):4462-76.  2011
  105. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Authors: Jiao Y, Ou W, Meng F
    Mol. Cancer, 2011;10(0):125.  2011
  106. Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation.
    Authors: Csepeggi C, Jiang M, Kojima F
    J. Biol. Chem., 2011;286(3):2078-87.  2011
  107. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Authors: Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S
    Clin. Cancer Res., 2010;16(22):5436-46.  2010
  108. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Authors: Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T
    Clin. Cancer Res., 2010;16(22):5489-98.  2010
  109. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.
    Authors: Cook SA, Varela-Carver A, Mongillo M
    Eur. Heart J., 2010;31(1):100-11.  2010
  110. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
    Authors: Ding W, Knox TR, Tschumper RC
    Blood, 2010;116(16):2984-93.  2010
  111. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
    Authors: Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S
    Mol. Cancer Ther., 2010;9(5):1286-97.  2010
  112. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells.
    Authors: Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH
    Mol. Cancer Ther., 2010;9(5):1396-407.  2010
  113. Coactivated platelet-derived growth factor receptor alpha and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
    Authors: Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M
    Cancer Res., 2010;70(18):7304-14.  2010
  114. Somatic cell plasticity and Niemann-pick type C2 protein: adipocyte differentiation and function.
    Authors: Csepeggi C, Jiang M, Frolov A
    J. Biol. Chem., 2010;285(39):30347-54.  2010
  115. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Authors: Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Perez-Martinez MC, Cufi S, Del Barco S, Bernado L, Brunet J, Lopez-Bonet E, Menendez JA
    Int. J. Oncol., 2010;37(3):669-78.  2010
  116. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
    Authors: Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, Jocolle G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S
    Clin. Cancer Res., 2010;16(14):3581-93.  2010
  117. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
    Authors: Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M
    Cancer Cell, 2010;18(6):683-95.  2010
  118. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Authors: Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS
    Nature, 2010;468(7326):973-7.  2010
  119. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.
    Authors: Roorda BD, Ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Kamps WA, de Bont ES
    Eur. J. Cancer, 2010;46(5):974-82.  2010
  120. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
    Authors: Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A
    Br. J. Cancer, 2010;103(2):196-200.  2010
  121. Decorin is a novel antagonistic ligand of the Met receptor.
    Authors: Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV
    J. Cell Biol., 2009;185(4):743-54.  2009
  122. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells.
    Authors: Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E
    Kidney Int., 2009;75(11):1173-83.  2009
  123. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
    Authors: Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY
    Mol. Cancer Ther., 2009;8(9):2526-36.  2009
  124. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells.
    Authors: Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, Tichy B, Dvorakova D, Pospisilova S, Hampl A, Dvorak P
    Stem Cells, 2009;27(8):1847-57.  2009
  125. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
    Authors: Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD
    Cancer Res., 2009;69(7):2996-3003.  2009
  126. Response to sunitinib malate in advanced alveolar soft part sarcoma.
    Authors: Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S
    Clin. Cancer Res., 2009;15(3):1096-104.  2009
  127. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
    Authors: Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF
    Br. J. Cancer, 2009;100(6):941-9.  2009
  128. Human cancers converge at the HIF-2alpha oncogenic axis.
    Authors: Franovic A, Holterman CE, Payette J, Lee S
    Proc. Natl. Acad. Sci. U.S.A., 2009;106(50):21306-11.  2009
  129. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Authors: Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y
    Carcinogenesis, 2009;30(7):1097-105.  2009
  130. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.
    Authors: Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, Skowronska A, Mapp K, Sameith K, Powell JE, Lawson S, Kearns P, Falciani F, Taylor M, Stankovic T
    Blood, 2009;113(1):117-26.  2009
  131. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Authors: Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stavale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C
    Clin. Cancer Res., 2009;15(18):5753-61.  2009
  132. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells.
    Authors: Kashiwagi K, Virgona N, Harada K, Kido W, Yano Y, Ando A, Hagiwara K, Yano T
    Life Sci., 2009;84(19):650-6.  2009
  133. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
    Authors: Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA
    Clin. Cancer Res., 2008;14(13):4275-83.  2008
  134. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
    Authors: Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Dixon D
    Mol. Med., 2008;14(5):264-75.  2008
  135. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
    Authors: Mueller KL, Hunter LA, Ethier SP, Boerner JL
    Cancer Res., 2008;68(9):3314-22.  2008
  136. Molecular characterization of pediatric gastrointestinal stromal tumors.
    Authors: Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR
    Clin. Cancer Res., 2008;14(10):3204-15.  2008
  137. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Authors: Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B
    Cancer Res., 2008;68(7):2340-8.  2008
  138. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
    Authors: Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI
    Cancer Res., 2008;68(14):5827-38.  2008
  139. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Authors: Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS
    Cancer Res., 2008;68(20):8322-32.  2008
  140. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.
    Authors: Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K, Shiratori Y
    J. Biol. Chem., 2007;282(12):8741-8.  2007
  141. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Authors: Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA
    Science, 2007;316(5827):1039-43.  2007
  142. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Authors: Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA
    Science, 2007;318(5848):287-90.  2007
  143. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
    Authors: Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD
    J. Biol. Chem., 2007;283(2):739-50.  2007
  144. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling.
    Authors: Wang L, Schulz TC, Sherrer ES, Dauphin DS, Shin S, Nelson AM, Ware CB, Zhan M, Song CZ, Chen X, Brimble SN, McLean A, Galeano MJ, Uhl EW, D'Amour KA, Chesnut JD, Rao MS, Blau CA, Robins AJ
    Blood, 2007;110(12):4111-9.  2007
  145. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation.
    Authors: Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA, Kielty CM
    Biochem. J., 2007;405(3):417-28.  2007
  146. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.
    Authors: Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH
    Cancer Res., 2007;67(7):3094-105.  2007
  147. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors.
    Authors: Ball SG, Shuttleworth CA, Kielty CM
    J. Cell Biol., 2007;177(3):489-500.  2007
  148. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
    Authors: Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR
    Cancer Res., 2006;66(12):6296-303.  2006
  149. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Authors: Menendez JA, Mehmi I, Lupu R
    J. Clin. Oncol., 2006;24(23):3735-46.  2006
Expand to show all Citations

FAQs

No product specific FAQs exist for this product, however you may

View all Proteome Profiler Antibody Array FAQs
Tocris Peptides
Description Application Cat# Citations Images  

Leupeptin hemisulfate

1167 1  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Pepstatin A

1190 1  
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....
Average Rating: 5 (Based on 1 review)

Have you used Proteome Profiler Human Phospho-RTK Array Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Read what people are saying who have used Proteome Profiler Human Phospho-RTK Array Kit.

Filter by Ratings
Excellent
(1)
All Ratings
Filter by Applications
All Applications
Filter by Species
All Species

Images Ratings Applications Species Reviewed By Date Details
 Proteome Profiler Human Phospho-RTK Array Kit ARY001B Array ARY001B
Enlarge
Excellent
  Anonymous 10/20/2017
Show
Image Details
 Proteome Profiler Human Phospho-RTK Array Kit ARY001B
: Proteome Profiler Human Phospho-RTK Array Kit [ARY001B].

Please scroll the above reviews for more

Order Details

Contact Us to Order
reload

Feedback

Customer Information
R&D Systems Guarantee